Identification of small-molecule inhibitors of USP2a

• DOI: 10.1016/j.ejmech.2018.03.009
• Publication Date: 2018-03-05T17:14:14Z
• Authors: Marcin D. Tomala; Katarzyna Magiera...; Katarzyna Kubica; Sylwia Krzanik; Bartosz Zieba; Bogdan Musielak; Marcin Pustula; Grzegorz M. Popowicz; Michael Sattler; Grzegorz Dubin; Lukasz Skalniak; Tad A. Holak
• Keywords: Small Molecule Libraries; Structure-Activity Relationship; 0303 health sciences; 03 medical and health sciences; Dose-Response Relationship, Drug; Molecular Structure; Endopeptidases; Deubiquitinase ; Ubiquitin ; Small-molecular Inhibitors ; Heterocyclics ; Anticancer; Humans; Enzyme Inhibitors; Ubiquitin Thiolesterase; 3. Good health

USP2a is a deubiquitinating protease that rescues its target proteins from destruction by the proteasome by reversing the process of protein ubiquitination. USP2a shows oncogenic properties in vivo and has been found to be a specific activator of cyclin D1. Many types of cancers are addicted to cyclin D1 expression. Targeting USP2a is a promising strategy for cancer therapy but little progress has been made in the field of inhibition of USP2a. Using NMR-based fragment screening and biophysical binding assays, we have discovered small molecules that bind to USP2a. Iterations of fragment combination and structure-driven design identified two 5-(2-thienyl)-3-isoxazoles as the inhibitors of the USP2a-ubiquitin protein-protein interaction. The affinity of these molecules for the catalytic domain of USP2a parallels their ability to interfere with USP2a binding to ubiquitin in vitro. Altogether, our results establish the 5-(2-thienyl)-3-isoxazole pharmacophore as an attractive starting point for lead optimization.